雷那诺龙 | 565-99-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 雷那诺龙
• 英文名称: 3α-hydroxy-5β-pregnane-11,20-dione
• 英文别名: 11-Ketopregnanolone；Renanolone；(3R,5R,8S,9S,10S,13S,14S,17S)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one
• CAS: 565-99-1
• 化学式: C₂₁H₃₂O₃
• 分子量: 332.483
• InChiKey: DUHUCHOQIDJXAT-CSXWOMMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  雷那诺龙 在 吡啶 、 sodium iodide 作用下， 以 氯仿 、 丙酮 为溶剂， 生成 3α-Hydroxy-5β-pregnan-11,20-dion-iodacetat
  参考文献：
  名称：

  一些类固醇对小鼠中枢神经系统的作用。一，综合方法。

  摘要：

  DOI：

  10.1021/jm00328a003
• 作为产物：
  描述：

  11,20-二氧代-5-beta-孕甾烷-3-alpha-基乙酸酯 在 氢氧化钾 作用下， 生成 雷那诺龙
  参考文献：
  名称：

  关于肾上腺皮质成分及相关物质。沟通68。孕烷二醇-（3α，11α）-一-（20）和孕烷二醇-（3β，11α）-一-（20）

  摘要：

  DOI：

  10.1002/hlca.194402701107

文献信息

• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF NEUROSTEROIDS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES
  申请人：PURETECH LYT INC

  公开号：WO2021159021A1

  公开（公告）日：2021-08-12

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统导向的脂质前药、其药物组合物、制备此类前药和组合物的方法，以及提高包含在脂质前药中的治疗剂的生物利用度或其他特性的方法。本发明还提供了治疗如本文所述的疾病、紊乱或状况的方法，包括向有需要的患者施用所述的脂质前药或其药物组合物。
• Structural requirements in 20-oxo-steroids for interaction with the catalytic site of 20.BETA.-hydroxysteroid dehydrogenase.
  作者：TAKAO HAYAKAWA、TSUYOSHI TANIMOTO、JIRO KAWAMURA

  DOI：10.1248/cpb.28.730

  日期：——

  Kinetic measurements were made to investigate the interaction of 20β-hydroxysteroid dehydrogenase and a series of steroids with C-17 and/or C-21 hydroxyl groups, and the role of the region around C-17 and C-21 on the interaction of the reacting 20-oxo group with the catalytic site of the enzyme was considered. Substitution of a hydroxyl group for hydrogen at C-21 of 17-deoxy-steroid derivatives caused a significant decrease in the apparent Vmax value (to about one-sixth to one-ninth), but a slight increase in the apparent Km value (about 1.1- to 1.8-fold). The same change at C-21 of 17-hydroxy-steroid derivatives caused little or no decrease in the apparent Vmax value, but an increase in the apparent Km (about 1.4- to 1.8-fold) occurred which was similar to that with 17-deoxy-steroid derivatives. In 21-deoxy-11-deoxy-steroid derivatives, a 17α-hydroxyl substituent had little effect on the apparent Km value (about 0.8- to 1.1-fold) and produced a slight decrease in the apparent Vmax value (to about three-quarters to two-fifths). Introduction of a 17α-hydroxyl group into 21-deoxy-11-oxo-steroid derivatives led to a significant decrease in the apparent Km value (to about one-seventh) and a moderate decrease in the apparent Vmax value (to about five-sixths to one-half). Introduction of a 17α-hydroxyl group into 21-hydroxy-steroid derivatives caused the apparent Vmax value to increase by about 1.8- to 11-fold, but caused little or no decrease in the apparent Km value. These results suggest that the hydroxyl group at the 21- or 17α-position directly restricted the conformation and the orientation of the 20-oxo group towards the catalytic site of the enzyme and influenced the hydrogen transfer stage in the catalytic process, and also that, of the substituents at the 21- and 17α-positions, the latter may preferentially affect the reaction efficiency of the 20-oxo group. The presence of an oxo group at C-11 had an indirect influence on the effects of the substituents at the 21- and 17α-positions. The optimum orientation of the 20-oxo group for the catalytic reaction may occur in 21-deoxy-17-deoxy-11-deoxy-steroid derivatives. In an ideal ternary complex, the 20-oxo group of the steroid may project towards the β-face of the steroid ring and the conformation between the 20-oxo group and α-hydrogen of C-17 is nearly staggered, while that between C-21 and the α-hydrogen of C-17, looking along the C-17 to C-20 axis, is in a skew form ; the 20-oxo group is orientated rather far from the methyl group at the β-position of C-13 and more towards the β-chain of C-16.

  进行了动力学测量，以研究20β-羟类固醇脱氢酶与一系列具有C-17和/或C-21羟基的类固醇之间的相互作用，并考虑了C-17和C-21附近区域对反应的20-氧基与酶催化位点相互作用的影响。将C-21的氢替换为羟基的17-脱氧类固醇衍生物导致表观Vmax值显著下降（降至约六分之一到九分之一），但表观Km值略微增加（约1.1到1.8倍）。在17-羟基类固醇衍生物的C-21处进行相同的改变对表观Vmax值几乎没有或没有造成下降，但表观Km值却增加（约1.4到1.8倍），这与17-脱氧类固醇衍生物的变化相似。在21-脱氧-11-脱氧类固醇衍生物中，17α-羟基取代体对表观Km值影响不大（约0.8到1.1倍），并导致表观Vmax值轻微下降（降至约三分之四到五分之二）。在21-脱氧-11-氧基类固醇衍生物中引入17α-羟基使表观Km值显著降低（降至约七分之一），而表观Vmax值中度下降（降至约五分之六到一半）。在21-羟基类固醇衍生物中引入17α-羟基使表观Vmax值增加约1.8到11倍，但对表观Km值几乎没有影响。这些结果表明，位于21或17α位点的羟基直接限制了20-氧基与酶催化位点之间的构象和取向，并影响了催化过程中的氢转移阶段。此外，在21和17α位点的取代基中，后者可能更优先影响20-氧基的反应效率。C-11的氧基的存在对21和17α位点取代基的影响具有间接作用。20-氧基在催化反应中的最佳取向可能发生在21-脱氧-17-脱氧-11-脱氧类固醇衍生物中。在一个理想的三元复合物中，类固醇的20-氧基可能朝向类固醇环的β面突出，且20-氧基与C-17的α-氢之间的构象几乎呈交错状态；而C-21与C-17的α-氢之间的角度在C-17至C-20轴上是倾斜的；20-氧基在空间上较远离C-13的β位甲基，更靠近C-16的β链。
• Steroidal anaesthetics of the pregnane and 19-norpregnane series
  申请人：Glaxo Laboratories Limited

  公开号：US03983111A1

  公开（公告）日：1976-09-28

  Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the steroids having a 3.alpha.-hydroxy group, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position a cyano, azido or basic amino group.

  描述了孕烷和19-去甲孕烷系列的类固醇麻醉药物，这些类固醇具有3.alpha.-羟基、17.alpha.-氢原子、20-酮基和在21-位置上的氰基、叠氮基或碱性氨基团。
• Allopregnanolone and Pregnanolone Analogues Modified in the C Ring: Synthesis and Activity
  作者：Barbora Slavíková、Jordi Bujons、Libor Matyáš、Miguel Vidal、Zoila Babot、Zdena Krištofíková、Cristina Suñol、Alexander Kasal

  DOI：10.1021/jm3016365

  日期：2013.3.28

  -one), the principal neurosteroid acting via γ-aminobutyric acid (GABA). These analogues were designed to study the structural requirements of the corresponding GABAA receptor. Their biological activity was measured by in vitro test with [3H]flunitrazepam as radioligand in which allopregnanolone and its active analogues stimulated the binding to the GABAA receptor. Analysis of the SAR data suggests

  （25 R）-3β-羟基-5α-spirostan-12-one（hecogenin）和11α-hydroxypregn-4-ene-3,20-dione（11α-hydroxyprogesterone）被用作合成一系列5ξ-孕烯醇酮的11位和12位取代衍生物（3α-羟基-5α-pregnan-20-one和3α-羟基-5β-pregnan-20-one），主要的神经固醇通过γ-氨基丁酸（GABA）起作用。设计这些类似物以研究相应的GABA A受体的结构要求。它们的生物学活性通过[ 3 H]氟硝西m作为放射性配体的体外试验进行测量，其中Allopregnanolone及其活性类似物刺激与GABA A的结合受体。SAR数据的分析表明，氟硝西binding的结合活性取决于C环边缘基团的疏水-亲水平衡，而不是它们与受体之间的特定相互作用。